Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Brents, Lisa K ^a   Reichard, Emily E ^a   Zimmerman, Sarah M ^a   Moran, Jeffery H ^a,b   Fantegrossi, William E ^a   Prather, Paul L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; [(1 (5 HYDROXYPENTYL) 1H INDOL 3 YL)(NAPHTHALEN 1 YL)METHANONE]; [(1 PENTYL 1H INDOL 3 YL) 1 NAPHTHALENYLMETHATHION]; [(4 HYDROXY 1 PENTYL 1H INDOL 3 YL)(NAPHTHALEN 1 YL)METHANONE]; [(5 HYDROXY 1 PENTYL 1H INDOL 3 YL)(NAPHTHALEN 1 YL)METHANONE]; [(6 HYDROXY 1 PENTYL 1H INDOL 3 YL)(NAPHTHALEN 1 YL)METHANONE]; [(7 HYDROXY 1 PENTYL 1H INDOL 3 YL)(NAPHTHALEN 1 YL)METHANONE]; [5 (3 (1 NAPHTHOYL) 1H INDOL 1 YL)PENTANOIC ACID]; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID DERIVATIVE; DRONABINOL; DRUG METABOLITE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); O 2050; UNCLASSIFIED DRUG; 1 PENTYL 3 (1 NAPHTHOYL)INDOLE; 1-PENTYL-3-(1-NAPHTHOYL)INDOLE; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; BRAIN HOMOGENATE; CONTROLLED STUDY; CORE TEMPERATURE; DRUG HYDROXYLATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN FUNCTION; ANIMAL; BODY TEMPERATURE; CHEMISTRY; DRUG DETOXIFICATION; DRUG EFFECT; DRUG POTENTIATION; HYDROXYLATION; METABOLISM; MOTOR ACTIVITY;

CANNABIS; CANNABIS SATIVA; MUS;

ANIMALS; BODY TEMPERATURE; HYDROXYLATION; INDOLES; METABOLIC DETOXICATION, PHASE I; MICE; MOTOR ACTIVITY; NAPHTHALENES; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 79960003774     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021917     Document Type: Article

References (61)

1. Vardakou I, Pistos C, Spiliopoulou C, (2010) Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197: 157-162.
2. Huffman JW, Dai D, Martin BR, Compton DR, (1994) Design, synthesis, and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 4: 563-566.
3. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, et al. (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285: 995-1004.
4. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, et al. (2009) 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44: 832-837.
5. EMCDDA-EuropolAddiction-Europol EMCfDaD, editor (2008) Annual Report on the implementation of Council Decision 2005/387/JHA. Lisbon, Portugal.
6. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y, (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo) 57: 439-441.
7. Chin CN, Murphy JW, Huffman JW, Kendall DA, (1999) The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther 291: 837-844.
8. Moller I, Wintermeyer A, Bender K, Jubner M, Thomas A, et al. (2010) Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal.
9. Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, et al. (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398: 2141-2153.
10. Atwood BK, Huffman J, Straiker A, Mackie K, (2010) JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160: 585-593.
11. (2009) World Drug Report Vienna, Austria United Nations.
12. Every-Palmer S, (2010) Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 105: 1859-1860.
13. Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, et al. (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118: 309-310.
14. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, et al. (2009) Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 106: 464-467.
15. Schneir AB, Cullen J, Ly BT, (2010) "Spice" Girls: Synthetic Cannabinoid Intoxication. J Emerg Med.
16. Vearrier D, Osterhoudt KC, (2010) A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 26: 462-465.
17. Wehrman J, (2010) Fake Marijuana Spurs More than 2,500 Calls to U.S. Poison Centers This Year Alone Alexandria, VA American Association of Poison Control Centers.
18. Muller H, Huttner HB, Kohrmann M, Wielopolski JE, Kornhuber J, et al. (2010) Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 43: 152-153.
19. Leonhart MM, Justice UDo, editor (2010) Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I. Federal Register pp. 71635-71638.
20. Showalter VM, Compton DR, Martin BR, Abood ME, (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
21. St. James J, (2010) Doctors concerned over possible link of K2, heart damage. WFAAcom Dallas/Fort Worth.
22. Maurer HH, Sauer C, Theobald DS, (2006) Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 28: 447-453.
23. Sobolevsky T, Prasolov I, Rodchenkov G, (2010) Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 200: 141-147.
24. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, et al. (2011) Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine. Anal Chem.
25. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87: 1932-1936.
26. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
27. Dennis I, Whalley BJ, Stephens GJ, (2008) Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes. Br J Pharmacol 154: 1349-1358.
28. Cascio MG, Bisogno T, Palazzo E, Thomas A, van der Stelt M, et al. (2006) In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. Br J Pharmacol 149: 431-440.
29. Aung MM, Griffin G, Huffman JW, Wu M, Keel C, et al. (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 60: 133-140.
30. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62: 588-631.
31. Childers SR, (2006) Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8: E112-117.
32. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, et al. (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270: 219-227.
33. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y, (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198: 31-38.
34. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, et al. (1995) Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 38: 3094-3105.
35. Zhang Q, Ma P, Cole RB, Wang G, (2006) Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal Bioanal Chem 386: 1345-1355.
36. Gorzalka BB, Hill MN, (2010) Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry.
37. Li C, Jones PM, Persaud SJ, (2011) Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther.
38. Watkins BA, Hutchins H, Li Y, Seifert MF, (2010) The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. J Nutr Biochem 21: 1141-1152.
39. Karst M, Wippermann S, Ahrens J, (2010) Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70: 2409-2438.
40. Bisogno T, Di Marzo V, (2010) Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 9: 564-573.
41. Bari M, Battista N, Pirazzi V, Maccarrone M, (2011) The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci 16: 498-516.
42. Rossi F, Bellini G, Luongo L, Torella M, Mancusi S, et al. (2011) The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy. Bone.
43. Holtkamp M, Meierkord H, (2007) Anticonvulsant, antiepileptogenic, and antiictogenic pharmacostrategies. Cell Mol Life Sci 64: 2023-2041.
44. Lutz B, (2004) On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 68: 1691-1698.
45. Bahremand A, Shafaroodi H, Ghasemi M, Nasrabady SE, Gholizadeh S, et al. (2008) The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res 81: 44-51.
46. Gholizadeh S, Shafaroodi H, Ghasemi M, Bahremand A, Sharifzadeh M, et al. (2007) Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 53: 763-770.
47. Hill AJ, Weston SE, Jones NA, Smith I, Bevan SA, et al. (2010) Delta-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51: 1522-1532.
48. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, et al. (2010) Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 332: 569-577.
49. Macdonald RL, Kang JQ, Gallagher MJ, (2010) Mutations in GABAA receptor subunits associated with genetic epilepsies. J Physiol 588: 1861-1869.
50. Mares P, Mikulecka A, Ticha K, Lojkova-Janeckova D, Kubova H, (2010) Metabotropic glutamate receptors as a target for anticonvulsant and anxiolytic action in immature rats. Epilepsia 51 (Suppl 3): 24-26.
51. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M, (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9: 413-424.
52. Heinz A, Schlagenhauf F, (2010) Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 36: 472-485.
53. Halberstadt AL, Geyer MA, (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology.
54. Javitt DC, (2010) Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 47: 4-16.
55. Deyama S, Takishita A, Tanimoto S, Ide S, Nakagawa T, et al. (2010) Roles of beta- and alpha2-adrenoceptors within the central nucleus of the amygdala in the visceral pain-induced aversion in rats. J Pharmacol Sci 114: 123-126.
56. Hurlemann R, Walter H, Rehme AK, Kukolja J, Santoro SC, et al. (2010) Human amygdala reactivity is diminished by the beta-noradrenergic antagonist propranolol. Psychol Med 40: 1839-1848.
57. Durant C, Christmas D, Nutt D, (2010) The pharmacology of anxiety. Curr Top Behav Neurosci 2: 303-330.
58. Prather PL, Martin NA, Breivogel CS, Childers SR, (2000) Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 57: 1000-1010.
59. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL, (2005) The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther 314: 868-875.
60. Liu JG, Prather PL, (2001) Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 60: 53-62.
61. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.